All News

The time has come for pharmacists to be considered healthcare providers under the Social Security Act.

A survey of new Rx and generic products

Herbal supplements are quite popular among your patients, but too few pharmacists are taking the time to properly educate about the risks.

Thinking about the future of pharmacy? Remember that you serve as a role model for the next generation of pharmacists.

The FDA recently approved teriflunomide for the treatment of patients with relapsing forms of multiple sclerosis.

In between the pharmacist activities that can be easily measured, you might find yourself engaging in conversations with your patients.

Readers discuss what rights pharmacists can expect and drug disposal options.

According to a recent FDA safety announcement, varenicline may pose an increased risk of cardiovascular events.

Many of the primary care worksite health centers managed by Walgreens Employer Solutions Group have received Medical Home accreditation from the Accreditation Association for Ambulatory Health Care (AAAHC), the company recently announced.

Last month NABP Executive Director Carmen Catizone, MS, RPh, unveiled an action plan to inspect nonresident compounding pharmacies and create a database to share regulatory information about these pharmacies with the state boards of pharmacy nationwide.

Collaboration between pharmacy benefit managers and community pharmacists may improve patient compliance to vital drug regimens.

This year the National Association of Chain Drug Stores (NACDS) is offering a one-of-a-kind business opportunity by combining its three trade shows-the Marketplace Conference, the Pharmacy and Technology Conference, and the Supply Chain & Logistics Conference-into one, Total Store Expo.

After a few slow years, experts believe that there's reason to hope that 2013 might bring some recovery.

In a drug safety communication, FDA has recommended that the bedtime dose of zolpidem, for the treatment of insomnia, be lowered because new data show that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving.

FDA’s recent approval of crofelemer (Fulyzaq, Salix Pharmaceuticals, under license from Napo Pharmaceuticals), 125-mg delayed-release tablets, the first anti-diarrheal drug for HIV/AIDS patients taking antiretroviral therapy (ART), is a significant step forward in addressing the unmet medical need of people with HIV/AIDS on ART who experience noninfectious diarrhea, which often can lead to reduced treatment compliance.

FDA issued a draft guidance on Jan. 9 to help industry in the development of opioid drug formulations with abuse-deterrent properties, saying it considers development of these products a high public health priority.

Changes in tablet color significantly increase the odds that patients will stop taking their medications, according to a study published online first Dec. 31, 2012, in JAMA Internal Medicine (formerly known as the Archives of Internal Medicine).

FDA announced recently it approved apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Distributing naloxone to heroin users may be a cost-effective way to reduce the number of overdose deaths, a new study finds.

A recent study found no increased risk of stillbirth, neonatal death, or postneonatal death in infants born to women who used a selective serotonin reuptake inhibitor (SSRI) prescription during their pregnancies.

The flu is hitting 29 states particularly hard this year, and more people are seeking their healthcare provider, according to a recent report from the Centers for Disease Control and Prevention (CDC).

The American Academy of Pediatrics (AAP) has published a policy statement to provide pediatricians with recommendations for assessing and treating Clostridium difficile infections (CDI) in children.

Governor Deval Patrick of Massachusetts filed legislation on Jan. 4, to reform the state Board of Pharmacy and strengthen oversight of the compounding pharmacy industry in the state.